Cited by 116

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Disabled-2 inactivation is an early step in ovarian tumorigenicity

Fazili, Zia, Sun, Wenping, Mittelstaedt, Stephen, Cohen, Cynthia, Xu, Xiang-Xi·1999·Oncogene

Abstract

Disabled-2 (Dab2) functions in mitogenic signal transduction pathway, and is frequently activated by homozygous gene deletion in tumors, suggesting that Dab2 is a candidate tumor suppressor. Here, we surveyed the expression of Dab2, and report that Dab2 is expressed in a variety of tissues, and the level of expression is particularly high in ovary and breast. Dab2 expression was also detected in immortalized breast and ovarian epithelial cells. However, in more than a dozen established tumor cell lines derived from breast and ovarian epithelial tumors examined by Western blotting, Dab2 expression was undetectable in 90% of these cell lines. Histological staining of human ovarian tissues with specific anti-Dab2 antibodies indicated that Dab2 is highly expressed in the surface epithelial layer. In an immunohistological study of 26 ovarian carcinomas, 22 (85%) of the tumors were found to lose the expression of Dab2 in the tumor cells, which are epithelial origin. Loss of Dab2 expression is not correlated with tumor grade, suggesting that Dab2 is lost in an early stage of tumorigenicity. Indeed, loss of Dab2 correlates closely with morphological transformation of the surface epithelial cells. Additionally, loss of Dab2 protein occurs in hyperproliferative, but histological benign ovarian epithelium, suggesting that loss of Dab2 occurs in pre-malignant lesions. Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding t…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1202649

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dab2 is expressed widely in most tissues and particularly abundantly in the kidney.

    “An initial survey indicated that Dab2 is expressed widely in most tissues and particularly abundantly in the kidney (Fazili et al., 1999)”

    From Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice (2016) · cites this paper as Fazili et al., 1999

  • Dab2 is widely expressed in mammals, whereas Dab1 is restricted to brain.

    “In mammals, Dab2 is widely expressed (Xu et al., 1998; Fazili et al., 1999), but Dab1 is restricted to brain (Howell et al., 1997; Sheldon et al., 1997).”

    From Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice (2016) · cites this paper as Fazili et al., 1999

  • Loss of Dab2 expression occurs in about 90% of ovarian cancer and is an early event in ovarian tumorigenicity.

    “Systematic analysis of a large panel of ovarian carcinomas showed that loss of Dab2 expression occurs in about 90% of ovarian cancer, and is an early event in ovarian tumorigenicity (Fazili et al., 1999).”

    From Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice (2016) · cites this paper as Fazili et al., 1999

  • Follow-up studies corroborated the loss of Dab2 expression in ovarian and breast cancer and its cell growth suppressive activity, and substantiated the proposal for Dab2 as a tumor suppressor.

    “Follow up studies corroborated the loss of Dab2 expression in ovarian and breast cancer and its cell growth suppressive activity, and substantiated the proposal for Dab2 as a tumor suppressor (Mok et al., 1998; Fazili et al., 1999).”

    From Endocytosis and Physiology: Insights from Disabled-2 Deficient Mice (2016) · cites this paper as Fazili et al., 1999

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. Albertsen HM, Smith SA, Melis R, William B, Holik P, Stevens J and White R. . 1996 Genomics 33: 207–213. · DOI
  2. Bast Jr RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M and Berchuck A. . 1993 Cancer 15: 1597–1601. · DOI
  3. Bell DA. . 1991 Human Path. 22: 750–762. · DOI
  4. Berchuck A and Carney M. . 1997 Biochem. Pharmacol. 54: 541–544. · DOI
  5. Bork P and Margolis B. . 1995 Cell 80: 693–694. · DOI · Paper page
  6. Cherniack AD, Klarlund JK, Conway BR and Czech MP. . 1995 J. Biol. Chem. 270: 1485–1488. · DOI
  7. Clark GJ and Der CJ. . 1995 Breast Cancer Res. Treat. 35: 133–144. · DOI
  8. D'Arcangelo G, Nakajima K, Miyata T, Ogawa M, Mikoshiba K and Curran T. . 1997 J. Neurosci. 17: 23–31. · DOI · Paper page
  9. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K; Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. . 1994 Science 266: 120–122. · DOI
  10. Gertler FB, Bennett RL, Clark ML and Hoffmann FM. . 1989 Cell 58: 103–113. · DOI · Paper page
  11. Gertler FB, Hill KH, Clark ML and Hoffmann FM. . 1993 Genes & Develop. 7: 441–453. · DOI · Paper page
  12. Godwin AK, Testa JR and Hamilton TC. . 1993 Cancer 71: 530–536. · DOI
  13. Howell BW, Gertler FB and Cooper JA. . 1997a EMBO J. 16: 121–132. · DOI · Paper page
  14. Howell BW, Hawkes R, Soriano P and Cooper JA. . 1997b Nature 389: 733–737. · DOI · Paper page
  15. Kavanaugh VM and Williams LT. . 1994 Science 266: 1862–1865. · DOI
  16. Knudson AG. . 1993 Proc. Natl. Acad. Sci. USA 90: 10914–10921. · DOI
  17. Lim WA, Richards FM and Fox RO. . 1994 Nature 372: 375–379. · DOI
  18. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. . 1994 Science 266: 66–71. · DOI
  19. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC and Berkowitz RS. . 1994 Gynecol. Oncol. 52: 247–252. · DOI · Paper page
  20. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini CV, Rock CO and Berkowitz RS. . 1998 Oncogene 16: 2381–2387. · DOI · Paper page
  21. Ren R, Mayer BJ, Cicchetti P and Baltimore D. . 1993 Science 259: 1157–1161. · DOI
  22. Stenback F and Wasenius VM. . 1985 Eur. J. Obstet. Gynecol. Reprod. Biol. 20: 357–371. · DOI
  23. Szabo CI and King MC. . 1995 Hum. Mol. Genet. 4: 1811–1817. · DOI
  24. Ware ML, Fox JW, Gonzalez JL, Davis NM, Lambert de Rouvroit C, Russo CJ, Chua Jr SC and Goffinet AM. . 1997 Neuron 19: 239249. · DOI
  25. Waters SB, Yammauchi K and Pessin J. . 1995 Mol. Cell. Biol. 15: 2791–2799. · DOI
  26. Wingo PA, Tong T and Bolden S. . 1995 CA Cancer J. Clin. 45: 8–30. · DOI
  27. Wittekind M, Mapelli C, Farmer II BF, Suen KL, Goldfarb V, Tsao J, Lavoie T, Barbacid M, Meyers CA and Mueller L. . 1994 Biochem. 33: 13531–13539. · DOI
  28. Xu XX, Yang W, Jackowski S and Rock CO. . 1995 J. Biol. Chem. 270: 14184–14191. · DOI · Paper page
  29. Xu XX, Yi T, Tang B and Lambeth JD. . 1998 Oncogene 16: 1561–1569. · DOI
  30. Zheng J, Benedict WF, Xu HJ, Hu SX, Kim TM, Velicescu M, Wan M, Cofer KF and Dubeau L. . 1995 J. Natl. Cancer Inst. 15: 1146–1153. · DOI
  31. Zhou DJ, Gonzalez-Cadavid N, Ahuja H, Battifora H, Moore GE and Cline MJ. . 1988 Cancer 62: 1573–1576. · DOI

Cited by

Sorted by citations

Metadata

Authors
Fazili, Z., Sun, W., Mittelstaedt, S., Cohen, C., & Xu, X.-X.
Venue
Oncogene
Published
1999-05-20
Volume
18
Issue
20
Pages
3104-3113
ISSN
  • 0950-9232
  • 1476-5594
Cited by
116
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review